Login to Your Account

Dendreon Shows Survival Benefit In Phase III Study Of Provenge

By Jennifer Boggs

Friday, February 18, 2005
A month after reporting a miss in a Phase III trial of its prostate cancer drug Provenge, Dendreon Corp. rebounded with data from the study showing a statistical improvement in patient survival rate. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription